Evekeo (amphetamine sulfate; Arbor) tablets administered once or twice daily to children aged 6–12 years was effective in treating attention deficit hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting. Findings from the study are published in the Journal of Child and Adolescent Psychopharmacology.
Study authors compared the safety and efficacy of Evekeo vs. placebo with rating scales and performance measures that assessed ADHD symptoms, in addition to behavior and productivity in the classroom. A single daily dose of Evekeo led to significant improvement in ADHD rating scores on laboratory class room days, beginning at 45 minutes post-dose through 10 hours. Scores for ADHD signs and symptoms also improved among children receiving twice daily Evekeo during the initial dose-optimization phase.
Evekeo, a CII controlled substance, is approved for the treatment of ADHD in children ≥3 years old. It is also approved for the treatment of narcolepsy in patients aged ≥6 years, and for exogenous obesity as a short-term adjunctive therapy in a regimen of weight reduction in patients aged ≥12 years. It is available in 5mg and 10mg strength tablets in 100-count bottles.
For more information call (866) 516-4950 or visit Evekeo.com.